Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $150.0 million.

  • Arcus Biosciences' Cash & Equivalents rose 18.41% to $238.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year increase of 18.41%. This contributed to the annual value of $150.0 million for FY2024, which is 18.11% up from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Cash & Equivalents is $150.0 million, which was up 18.11% from $127.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Cash & Equivalents ranged from a high of $206.0 million in FY2022 and a low of $127.0 million during FY2023.
  • For the 3-year period, Arcus Biosciences' Cash & Equivalents averaged around $161.0 million, with its median value being $150.0 million (2024).
  • As far as peak fluctuations go, Arcus Biosciences' Cash & Equivalents skyrocketed by 199.32% in 2020, and later plummeted by 38.35% in 2023.
  • Yearly analysis of 5 years shows Arcus Biosciences' Cash & Equivalents stood at $173.4 million in 2020, then decreased by 14.66% to $148.0 million in 2021, then spiked by 39.19% to $206.0 million in 2022, then plummeted by 38.35% to $127.0 million in 2023, then increased by 18.11% to $150.0 million in 2024.